KHKhwaja Saad Haq

Khwaja Saad Haq

*This is an algorithmically generated author record based on publicly available information.

Khwaja Saad Haq has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unveiling the Unexpected: Duodenal Ulcer as a Manifestation of Breast Cancer Metastasis

    by Emmanuel Gbadehan, Mohammad Abubaker, Parth Adrejiya, Khwaja Haq, Teresa Varghese, Joy Chaudhari, Gurkeerat Singh, Ashok Kanugula

    Breast cancer typically metastasizes to the lymph nodes, lungs, bones, and liver. However, gastrointestinal (GI) involvement is exceedingly rare, particularly presenting as duodenal ulcers. Such metastases often mimic primary GI malignancies, leading to nonspecific symptoms like abdominal pain, anorexia, bleeding, and vomiting, which can delay accurate diagnosis. Early recognition through appropriate diagnostic evaluations is crucial to prevent disease progression. We report a unique case of an 86-year-old woman with multiple comorbidities who presented with multiple gastrointestinal ulcers. Further investigation revealed these lesions to be manifestations of metastatic breast cancer. This case underscores the importance of considering metastatic breast cancer in the differential diagnosis of atypical gastrointestinal presentations, even in elderly patients without a known history of malignancy.

  • Open Access

    Impact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database

    by Tijin A. Mathew, Teresa M. Varghese, Nithya Krishnakumaran, George M. Varghese, Khwaja S. Haq, Akshita Khosla, Rojymon Jacob, Gina Vaccaro

    Background: Cholangiocarcinoma, malignancies arising from the intrahepatic and extrahepatic bile ducts, has increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in specific racial groups such as Asian and Pacific Islander patients. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African American, Hispanic, Asian or Pacific Islander, Native American, and Other. The data analysis was performed using STATA/BE version 18.5. Univariable and multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were White, 13.27% Hispanic, and 10.13% African American. There was a statistically significant difference in gender distribution across racial groups (p < 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among the Hispanic group. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p < 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African American, Native American, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.

  • Open Access

    Impact of Race on Admission, Clinical Outcomes, and Disposition in Cholangiocarcinoma: Insights from the National Inpatient Database

    by Tijin Ann Mathew, Teresa M Varghese, Nithya Krishnakumaran, George M Varghese, Khwaja Saad Haq, Akshita Khosla, Rojymon Jacob, Gina Vaccaro

    Background: Cholangiocarcinoma, malignancies arising from intrahepatic and extrahepatic bile ducts, have increased in incidence in the United States over the past few decades. The reported incidence of cholangiocarcinomas is high, particularly in certain racial groups such as Asian and Pacific Islanders. Race also significantly impacts disparities in healthcare utilization and clinical outcomes. Our study focused on the impact of race on admission, clinical outcomes, and disposition of cholangiocarcinoma. Methods: We performed a retrospective analysis of cholangiocarcinoma-related hospital admissions, using the National Inpatient Sample for the year 2022. Patients were stratified according to race into the following groups: White, African Americans, Hispanics, Asian or Pacific Islanders, Native Americans, and Others. The data analysis was performed using STATA/BE version 18.5. Univariate and Multivariable logistic regression models were applied to evaluate the relationship between race and clinical and healthcare utilization outcomes. Results: In 2022, 7479 hospitalizations were recorded for cholangiocarcinoma in the United States. Among these, 65.99% were Whites, 13.27% Hispanics, and 10.13% African-Americans. There was a statistically significant difference in gender distribution across racial groups (p< 0.001), with males comprising the majority in all groups. Males outnumbered females in all racial groups except among Hispanics. Significant racial disparities in mortality were observed, with White patients showing a mortality rate of 6.69%, compared to higher rates among African-American (9.76%), Native American (8.51%), and Asian or Pacific Islander (8.09%) patients, while Hispanic (5.04%) and Other (5.88%) groups had lower rates (p< 0.001). Conclusions: The study underscores the racial disparities among cholangiocarcinoma hospitalizations, with African Americans, Native Americans, and Asian patients facing disproportionately higher mortality and poorer in-hospital outcomes compared to White patients. This analysis highlights the healthcare strategies and policy reforms to promote equitable treatment by mitigating these disparities and to improve cholangiocarcinoma outcomes.